Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin

Journal of Clinical Psychopharmacology

Volumn 20, Issue 4, 2000, Pages 404-409

  Kondo, Tsuyoshi ^a   Mihara, Kazuo ^a   Yasui, Norio ^a   Nagashima, Udai ^a   Ono, Shingo ^a   Kaneko, Sunao ^a   Ohkubo, Tadashi ^b   Osanai, Takako ^b   Sugawara, Kazunobu ^b   Otani, Koichi ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EMILACE; EMONAPRIDE; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BIOTRANSFORMATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS;

EID: 0033941760     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200008000-00003     Document Type: Article

References (26)

1. 3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur J Pharmacol 1989;173:177-82.
2. Schotte A, Bonaventure P, Janssen PFM, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69:399-412.
3. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 1997;334:141-7.
4. Mori A, Kazamatsuri H, Kaneko S, Kamijima K, KariyaT, Murasaki M, Yagi G. A double-blind comparison of a new benzamide compound YM-09151 with haloperidol in the treatment of schizophrenia [article in Japanese]. Clin Eval 1989;17:349-77.
5. Satoh K, Someya T, Shibasaki M. Effects of nemonapride on positive and negative symptoms of schizophrenia. Int Clin Psychopharmacol 1996;11:279-81.
6. Lindenmayer J-P, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 1995;28:22-31.
7. Otani K, Kondo T, Yasui N, Suzuki A, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K, Hayashi K. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum Psychopharmacol 1997;12:591-4.
8. Bolvig Hansen L, Larsen N-E, Gulmann N. Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl) 1982;78:112-5.
9. Dahl SG. Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacokinet 1986;11:36-61.
10. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
11. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33:279-86.
12. Van Putten T, Marder SR, Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol 1991; 11:357-61.
13. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986;73[Suppl 326]:1-37.
14. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J Chromatogr 1998;714:293-8.
15. Bohm C, Placchi M, Stallone F, Gammans RE, Alms DR, Shrotriya RC, Robinson DS. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 1990;10[Suppl 3]:38S-42S.
16. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10[Suppl 3]:67S-76S.
17. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-79.
18. 2 receptors. Int Clin Psychopharmacol 1995;10:19-30.
19. Cowen PJ. Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 1991;160[suppl 12]:7-14.
20. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-4.
21. 4. Neuropsychopharmacology 1992;82:55-61.
22. Schwartz J-C, Levesque D, Martres M-P, Sokoloff P. Dopamine D3 receptor: basic and clinical aspects. Clin Neuropharmacol 1993; 16:295-314.
23. Koshiya K, Morita T, Usuda S. Behavioral suppressive and disinhibitory effects of nemonapride: possible biological basis of its antipsychotic efficacies [abstract]. Clin Neuropharmacol 1992; 15[suppl 1]:453B.
24. Rubin RT. Prolactin and schizophrenia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:803-8.
25. Harnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F-A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 1984;69[suppl 311]:75-92.
26. Linkowski P, Hubain P, Von Frenckell R, Mendlewicz J. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 1984;234:231-6.